AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Genenta Science Reports Consistent Survival Metrics for TEM-GBM Study Patients.
ByAinvest
Monday, Nov 24, 2025 4:03 am ET1min read
Genenta Science announced an update from its TEM-GBM study in newly diagnosed glioblastoma multiforme patients. As of November 21, 2025, 25 patients have been treated with Temferon, with key survival metrics remaining consistent. 44% of patients have reached 18-month survival, compared to 38% reported in April, and the two-year survival rate is 29%. Median overall survival remains at 17 months.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet